Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials

James J. Connolly¹, Kohtaro Ooka² and Joseph K. Lim*³

¹Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA; ²Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA, USA; ³Yale Liver Center, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT, USA

Abstract

Non-alcoholic steatohepatitis (NASH) results from inflammation and hepatocyte injury in the setting of hepatic steatosis. Non-alcoholic steatohepatitis increases the risk of progression to liver fibrosis and cirrhosis, and is the most rapidly growing etiology for liver failure and indication for liver transplantation in the USA. Weight loss and lifestyle modification remain the standard first-line treatment, as no USA Food and Drug Administration-approved pharmacotherapy currently exists. The past decade has seen an explosion of interest in drug development targeting pathologic pathways in non-alcoholic steatohepatitis, with numerous phase 2 and 3 trials currently in progress. Here, we concisely review the major targets and mechanisms of action by class, summarize results from completed pivotal phase 2 studies, and provide a detailed outline of key active studies with trial data for drugs in development, including obeticholic acid, elafibranor, cenicriviroc and selonsertib.

Citation of this article: Connolly JJ, Ooka K, Lim JK. Future pharmacotherapy for non-alcoholic steatohepatitis (NASH): Review of phase 2 and 3 trials. J Clin Transl Hepatol 2018;6(3):264–275. doi: 10.14218/JCTH.2017.00056.

Introduction

Non-alcoholic steatohepatitis (NASH), a subcategory of non-alcoholic fatty liver disease (NAFLD), is defined as the presence of hepatic steatosis and inflammation with hepatocyte injury.¹ Approximately one-quarter of the world’s population has NAFLD, with estimates of the prevalence of NASH ranging from 1.5% to 6.45%.² In the USA, this translates into an estimated $103 billion annual economic burden.³

NASH is currently the second leading etiology of cirrhosis among adults awaiting liver transplantation in the USA, and is expected to soon represent the leading indication for liver transplantation.⁵ There are currently no USA Food and Drug Administration (FDA) approved medications for the treatment of NASH. Current management is primarily focused on promoting weight loss through lifestyle interventions. Weight loss medications, bariatric surgery and bariatric endoscopy represent attractive future approaches for NASH, although there is limited prospective data to support their role in clinical practice, and they are not presently endorsed by the American Association for the Study of Liver Diseases.¹

In the last decade, the number of clinical trials of pharmacotherapies for the treatment of NASH has significantly increased. Several systematic reviews and meta-analyses have been conducted to aggregate data from published studies.⁶⁻⁷ Therapies investigated with questionable benefit have included metformin, thiazolidinediones, vitamin E and pentoxifylline. However, the heterogeneity of study design and inclusion criteria, modest cohort sizes, differences in reported outcomes (e.g., histologic characteristics), lack of fibrosis improvement, and uncertain long-term benefits and safety have limited interpretation of their therapeutic safety and efficacy. In this context, a growing cohort of clinical development programs evaluating novel pharmacotherapeutic agents for NASH has emerged, primarily focused on demonstrating improvement in histologic characteristics of NASH, including steatosis, steatohepatitis and fibrosis. The aim of this paper is to briefly summarize the targets for these future pharmacotherapies, with a focus on agents in phase 2 and 3 trials.

Methods

We searched ClinicalTrials.gov in May 2017 for phase 2 or 3 interventional studies that were open for enrollment or active but not enrolling and contained the phrase “non-alcoholic steatohepatitis”. Pediatric studies were not included. We did not include trials for nutritional supplements. When there were discrepancies between ClinicalTrials.gov and published materials (e.g., conference abstract), we used the information from the published materials.

Key targets and mechanisms of action

Drugs in trials for NASH are designed to attenuate lipotoxicity, whether by reducing lipid accumulation or by reducing downstream pathways that lead to hepatocyte injury, death and, in some, cirrhosis. Many drugs in phase 3 trials and those with results from phase 2 trials target lipid metabolism, inflammation or the formation of fibrous connective tissue within the liver (Fig. 1). Examples of agents that target lipid metabolism...
include farnesoid X nuclear receptor (FXR) agonists, fibroblast growth factor (FGF) variants and peroxisome proliferator-activated receptor (PPAR) agonists.

FXR is a bile acid receptor that regulates lipid and glucose metabolism. FXR activation leads to reduction in serum and hepatic triglyceride levels. Obeticholic acid is a semi-synthetic FXR agonist currently in a phase 3 trial (National clinical trial number [NCT]02548351).

FGF19 and FGF21 are circulating proteins that bind to FGF receptors (primarily FGR4 and FGR1c, respectively) with the cofactor β-Klotho. In animal models, FGF19 and FGF21 improve lipid profiles (decreasing triglycerides, low-density lipoprotein [LDL] and total cholesterol), improve glucose control, and lead to weight loss. In a recent study on animal models, FGF15 (the murine FGF19) fused with apolipoprotein reduced hepatic lipid and bile acid accumulation and improved survival. Similar results were seen in two phase 1 studies of FGF21 analogues in human subjects. BMS-986036, a pegylated FGF21, and NGM282, a synthetic FGF19 variant, are being studied in phase 2 trials (NCT02686762 and NCT02960204).

PPAR-δ and γ are transcription factors involved in lipid metabolism. PPAR-δ is implicated in fatty acid catabolism. PPAR-δ activation increases lipolysis cellular lipid uptake. Treatment with fibrates, which are PPAR-α ligands, reduces circulating triglycerides and increased HDL levels. In animal models, PPAR-δ activation leads to fatty acid consumption in skeletal muscle and adipose tissue. PPAR-γ may reduce hepatic steatosis by shifting fat deposition to adipose tissue. Rosiglitazone, a PPAR-γ agonist, has been shown to reduce liver fat content and laboratory markers of hepatocellular injury, but was also shown to increase cardiovascular risks. Elafibranor is a PPAR-α/δ agonist currently in a phase 3 trial (NCT02704403).

PPAR-α, δ and γ are transcription factors involved in lipid metabolism. PPAR-α is implicated in fatty acid catabolism. PPAR-α activation increases lipolysis cellular lipid uptake. Treatment with fibrates, which are PPAR-α ligands, reduces circulating triglycerides and increased HDL levels. In animal models, PPAR-δ activation leads to fatty acid consumption in skeletal muscle and adipose tissue. PPAR-γ may reduce hepatic steatosis by shifting fat deposition to adipose tissue. Rosiglitazone, a PPAR-γ agonist, has been shown to reduce liver fat content and laboratory markers of hepatocellular injury, but was also shown to increase cardiovascular risks. Elafibranor is a PPAR-α/δ agonist currently in a phase 3 trial (NCT02704403).

C-C motif chemokine receptor (CCR) 2 and CCR5 are chemokine receptors expressed on circulating monocytes as well as on Kupffer cells. Activation of these receptors induces migration of macrophages into the liver. Cenicriviroc (CVC) is a CCR2/5 antagonist in phase 2 and phase 3 trials (NCT02217475 and NCT03028740).

Caspases are key mediators of inflammation and apoptosis. Apoptosis is in, turn, profibrotic. Emtricitab (IDN-6556) is a pan-caspase inhibitor that is being studied in phase 2 trials (NCT02686762 and NCT02960204).

**Fig. 1. Key targets for drugs in phase 2 and phase 3 clinical trials.**

**Expedited FDA approval process**

The natural history of NASH is typically characterized by a time period of years to decades between the onset of fatty liver to the development of liver cirrhosis and its complications, including liver-related mortality. Regulatory endpoints focused on clinical outcomes such as progression to liver cirrhosis, liver failure, hepatocellular carcinoma, need for liver transplantation, and liver-related death are not feasible within a registration program. Based on evidence confirming the association of surrogate histologic and clinical endpoints and clinical outcomes, the FDA has established regulatory pathways which incorporate non-invasive, clinical and histologic endpoints for phase 2 and 3 clinical development, with the expectation for postmarketing clinical outcome evaluation in phase 4 studies.

Advances in the development of serum biomarkers, imaging and elastography have permitted their use as viable trial endpoints in early human studies, which inform the design of phase 2 trials using a primary endpoint of improvement of ≥2 points in the NAFLD activity score (NAS) including improvement in lobular inflammation or hepatocellular ballooning with no worsening in fibrosis. Phase 3 trials are focused on a primary endpoint of either NASH resolution without worsening of liver fibrosis, or liver fibrosis regression of at minimum one stage without worsening of NAS activity. Phase 4 studies are focused on long-term assessment of clinical outcomes (e.g., all-cause mortality, liver transplant, hepatic decompensation events), progression to cirrhosis, or an increase in model for end-stage liver disease score from <12 to ≥15. The development of surrogate biomarkers that are "reasonably likely to predict a drug's intended clinical benefit" and are independent of liver histology remains of great interest to clinicians, researchers, and the FDA.

Emtricitab (IDN-6556) is a pan-caspase inhibitor that is being studied in phase 2 trials (NCT02686762 and NCT02960204).

**Fig. 1. Key targets for drugs in phase 2 and phase 3 clinical trials.**
Summary of drugs in phase 2 and 3 trials

We identified eight active phase 3 studies (Table 1) and 23 active phase 2 studies (Table 2). Trials of nutritional supplements, such as “Synbiotics Supplement” (NCT02530138), curcumin (NCT02908152), resveratrol (NCT02216552), caffeine and cholic acid (NCT02929901), and CPAP (NCT01849081), were not included.

Drugs in phase 3 trials

Herein, we report key agents currently under evaluation within the eight ongoing or proposed phase 3 trials registered on ClinicalTrials.gov for the treatment of NASH (Table 1). One study of hydroxytyrosol and vitamin E for the treatment of children with NASH (NCT02842567) is not reviewed due to its focus on pediatric patients.

Obeticholic acid (OCA): OCA (Intercept Pharmaceuticals, New York, NY, USA) is a farnesoid X nuclear receptor (FXR) ligand that is currently being evaluated in the phase 3 study REGENERATE (NCT02548351) for the treatment of NASH. OCA was granted accelerated approval by the FDA in May 2016 for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults with an inadequate response or intolerance to ursodeoxycholic acid and marketed under the brand name Ocaliva.45

In a small phase 2 trial, treatment with OCA was shown to increase insulin sensitivity and reduce alanine aminotransferase levels and serum markers of fibrosis in patients with diabetes and NAFLD.46 Subsequently, OCA was studied in the phase 2b FLINT trial (NCT01265498), where 283 patients with non-cirrhotic NASH were randomized 1:1 to receive OCA 25 mg or placebo for 72 weeks (Table 3).47 The primary outcome was improvement in NAS by ≥2 points without worsening of fibrosis. In both the planned interim and the end of treatment cohorts, OCA demonstrated superiority over placebo in meeting the primary endpoint at 72 weeks on an intention-to-treat basis (45% vs. 21%, p = 0.0002), and in addition demonstrated improvement in liver fibrosis (35% vs. 19%, p = 0.004). Although well-tolerated, a trend for a small increase in LDL and decrease in HDL was identified, but was reversible with HMG-CoA reductase inhibitor therapy, resolved spontaneously upon withdrawal of OCA, and was not associated with any difference in cardiovascular events.48 Of note, however, are safety concerns, including liver injury, liver decompensation, liver failure and death, that have been reported for a small number of patients with moderate or severe hepatic impairment (Child-Pugh B/C) taking OCA for the treatment of PBC.49 Although these adverse events were specifically seen in patients with advanced cirrhosis, careful attention to the safety profile of OCA is warranted in phase 3 NASH trials in participants with both normal and impaired hepatic function.

Recruiting for the phase 3 REGENERATE trial began in 2015 with a target of 2000 participants with biopsy-proven, non-cirrhotic NASH to be randomized 1:1:1 to OCA 10 mg, OCA 25 mg or placebo groups. The two specified coprimary endpoints are liver fibrosis improving one stage without worsening of NASH, and NASH resolution with no worsening of fibrosis at 18 months. Other primary outcomes include death or liver-related adverse events at approximately 6 years. The target primary completion date is October 2021.

Elafibranor: Elafibranor (also known as GFT505) is a dual PPAR-a/δ agonist produced by GENFIT (Loos, France) that is currently undergoing evaluation in the phase 3 RESOLVE-IT trial (NCT02704403). The drug was granted "Fast Track" designation by the FDA in February 2014 for the treatment of NASH and received clearance by the FDA in November 2016 for evaluation in PBC.50,51

Elafibranor was tested in the phase 2b GOLDEN-505 trial (NCT01694849) which randomized 276 patients with NASH without cirrhosis to elafibranor 80 mg, elafibranor 120 mg or placebo groups in a 1:1:1 fashion (Table 3).52 The protocol-defined primary outcome was reversal of NASH on histologic NAS scoring with resolution of steatosis, ballooning, or inflammation without progression to bridging fibrosis or cirrhosis (if bridging fibrosis was evident at baseline) at 52 weeks. Although this primary endpoint was not met in the intention-to-treat analysis, a post-hoc analysis based on a modified definition of response (resolution of NASH defined by disappearance of ballooning with disappearance or mild persistence of lobular inflammation and a pathological diagnosis of steatosis with or without mild inflammation and no worsening of fibrosis) did confirm superiority of the 120 mg dose compared to placebo (19% vs. 12%, p = 0.045), with stronger response among participants with baseline moderate or severe NASH (20% vs. 11%, p = 0.018). Significant reduction in fibrosis was noted in patients who responded to the 120 mg dose based on the modified definition compared to those who did not. Furthermore, elafibranor was well tolerated, without causing weight gain or cardiac events, and both lipid/glucose profiles and markers of systemic inflammation were reduced. However, a mild, reversible increase in serum creatinine was observed.

The phase 3 RESOLVE-IT trial began in March 2016 with the goal of recruiting 2000 patients with biopsy-proven moderate or severe (F2-F3) NASH. Patients will receive either 120 mg of elafibranor or placebo. The primary endpoints include the proportion of patients with resolution of NASH without worsening of fibrosis and a composite long-term outcome (all-cause mortality, cirrhosis and liver-related clinical outcomes) at 72 weeks with estimated follow-up of 4 years. The study is actively recruiting with an estimated primary completion date in December 2021.

Selonsertib: Selonsertib (also known as GS-4997) is an apoptosis signal-regulating kinase 1 inhibitor produced by Gilead (Foster City, CA, USA) that is currently under evaluation in two phase 3 clinical trials (STELLAR-3 [NCT03053050] and STELLAR-4 [NCT03053063]) for the treatment of NASH. It is intended to reduce JNK- and p38 MAPK-mediated hepatic stellate cell activation and cytokine production.53

Early human studies revealed that selonsertib reduces inflammation and hepatocyte apoptosis.53 Selonsertib was studied in a phase 2, open label, randomized controlled trial (NCT02466516) conducted throughout the USA and Canada.54 It enrolled 72 adults with biopsy-proven NASH and randomized them to receive selonsertib 6 mg or 18 mg with or without simtuzumab for 24 weeks (Table 3). The study recruited participants with stage F2-F3 fibrosis and NAS ≥5. Selonsertib was determined to be superior to placebo in achieving the primary efficacy endpoint of fibrosis improvement of one stage or greater (43% of 18 mg, 30% of 6 mg and 20% of placebo-treated), as well as fibrosis improvement without worsening NASH (37% of 18 mg, 30% of 6 mg and 20% of placebo-treated) and progression to cirrhosis (3% of 18 mg, 7% of 6 mg and 20% of placebo-treated). However, there was no difference in achieving a decrease in NAS of at minimum two points (23% of 18 mg, 19% of 6 mg and 20% of placebo-treated) or NASH resolution (0% of 18 mg, 4% of 6 mg and 0% of placebo-treated).
Table 1. Active phase 3 clinical trials for the pharmacologic treatment of NASH registered on ClinicalTrials.gov

| Drug (Alias)       | Mechanism                  | Study Name                        | Target Completion Date | Target Enrollment | Inclusion Criteria                  | Primary Outcome Measures                                                                 |
|--------------------|-----------------------------|-----------------------------------|------------------------|-------------------|--------------------------------------|------------------------------------------------------------------------------------------|
| Obeticholic acid (OCA) | FXR ligand                  | REGENERATE (NCT02548351; Intercept Pharmaceuticals, New York, NY, USA) | Oct 2021              | 2000               | ≥4, with ≥1 of each component of the score, F1–3 | Biopsy • Histologic improvement - improvement in liver fibrosis and resolution of NASH at 18 months
|                    |                             |                                    |                        |                   |                                      | • Composite outcome - death, MELD ≥15, cirrhosis, transplant, HCC, hospitalization, others at 6 years (est.) |
| Elafibranor (GFT505) | PPAR-γδ agonist             | RESOLVE-IT (NCT02704403; Genfit, Loos, France) | Dec 2021               | 2000               | ≥4, with ≥1 of each component of the score, F1–3 | Biopsy • Histologic improvement - resolution of fibrosis at 72 weeks
|                    |                             |                                    |                        |                   |                                      | • Composite outcome - all-cause mortality, cirrhosis, “liver-related clinical outcomes” at 4 years (est.) |
| Selonsertib (GS-4997) | ASK-1 inhibitor              | STELLAR-3 and STELLAR-4 (NCT03053050 and NCT03053063; Gilead Sciences, Foster City, CA, USA) | Jan 2020               | 800 (each)         |                                      | Biopsy • Histologic improvement - ≥1 stage improvement in fibrosis without worsening of NASH at 48 weeks
|                    |                             |                                    |                        |                   |                                      | • Event-free survival at 240 weeks |
| Cenicriviroc (CVC)  | Dual CCR2/CCR5 antagonist    | AURORA (NCT03028740; Tobira Therapeutics, South San Francisco, CA, USA) | Jul 2019               | 2000               |                                      | Biopsy • Histologic improvement - ≥1 stage improvement in fibrosis without worsening of NASH at 12 months
|                    |                             |                                    |                        |                   |                                      | • Composite outcome - cirrhosis on histology, liver-related clinical outcomes, and all-cause mortality at 5 years (est.) |
| Liraglutide<sup>1</sup> | GLP-1 analogue              | CGH-LiNASH (NCT02654665; Changi General Hospital, Singapore) | Sep 2017               | 36                 |                                      | Liver chemistries, ultrasound, biopsy • Improvement in NAS at 12 months
|                    |                             |                                    |                        |                   |                                      | • Reduction/normalization in aminotransferases, liver fat at 12 months |
| Metadoxine         | Antioxidant (glutathione source) | (NCT02541045; Hospital General de Mexico, Mexico City, Mexico) | Aug 2018               | 108                | ≥3, with ≥1 of each component of the score, F0–2 | Biopsy • Improvement in NAS at 6 months |
| Hydroxytyrosol and vitamin E<sup>2</sup> | Antioxidant | (NCT02842567; Bambino Gesù Hospital and Research Institute, Rome, Italy) | Apr 2017               | 80                 |                                      | Biopsy • Laboratory markers of inflammation and oxidative stress at 4 months
|                    |                             |                                    |                        |                   |                                      | • Laboratory markers of metabolic syndrome at 4 months |

<sup>*</sup> Estimated primary completion date. All studies except NCT02842567 (hydroxytyrosol and vitamin E) were recruiting as of the date of data acquisition.

<sup>1</sup> Patients with stage 1 fibrosis were enrolled only if they have body mass index ≥30, diabetes mellitus type 2, or alanine aminotransferase elevation.

<sup>‡</sup> F2 or F3 fibrosis and “[a] group of patients with F1 fibrosis and concomitant cardiometabolic comorbidities, which are associated with rapid progression of the disease” (http://www.genfit.com/pipeline/elafibranor/).

<sup>3</sup> Compares liraglutide 0.6 mg subcutaneous injection daily increasing at 0.6 mg/week to a maximum of 3 mg to bariatric surgery and to lifestyle modification.

<sup>4</sup> Study of pediatric patients ages 4–16

Abbreviations: ASK, apoptosis signal-regulating kinase; CCR, C-C motif chemokine receptor; FXR, farnesoid X nuclear receptor; GLP, glucagon-like peptide; HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease score; NAS, NAFLD activity score [scored steatosis 0–3, ballooning 0–2, and lobular inflammation 0–3]; PPAR, peroxisome proliferator-activated receptor.
| Drug (Alias) | Mechanism | Study Name (ClinicalTrials.gov ID; Sponsor) | Target Completion Date | Target Enrollment | BMI as kg/m² | Fibrosis Stage | Diagnosis | Inclusion/Exclusion Criteria | Primary Outcome Measures |
|-------------|-----------|--------------------------------------------|-----------------------|------------------|--------------|---------------|-----------|-----------------------------|-------------------------|
| NGM282 (M70) | Variant of FGF-19 | (NCT02443116; NGM Biopharmaceuticals, San Francisco, CA, USA) | Apr 2018 | 82; planned for 140 | - | F1–3 | Biopsy | Imaging - ≥5% reduction in absolute liver fat content as measured by MRI at 12 weeks |
| BMS-986036 | Pegylated FGF-21 | (NCT02413372; Bristol-Myers Squibb, New York, NY, USA) | Jan 2017 | 74 | ≥25 | F1–3 | Biopsy | Imaging - hepatic fat fraction on MRI at 16 weeks |
| Emricasan (IDN-6556) | Caspase Inhibitor | ENCORE-NF (NCT02686762; Conatus Pharmaceuticals, San Diego, CA, USA) | Sep 2018 | 330 | - | F1–3 | Biopsy | Histologic improvement - improvement of fibrosis by at least one stage without worsening of steatohepatitis at 72 weeks |
| Emricasan (IDN-6556) | Caspase Inhibitor | ENCORE-PH (NCT02960204; Conatus Pharmaceuticals, San Diego, CA, USA) | Oct 2018 | 240 | - | F4 | Biopsy | Mean change in HVPG at 24 weeks |
| Aramchol | Synthetic lipid SCD1 inhibitor | (NCT02279524; Galmed Pharmaceuticals, Tel Aviv, Israel) | Mar 2018 | 240 | 25–40 | F0–3 | Biopsy | Change in triglyceride concentration on NMRS at 52 weeks |
| Atorvastatin and/or L carnitine | HMG-CoA reductase inhibitor/involved in lipid transport | (NCT01617772; Tehran University of Medical Sciences, Tehran, Iran) | Oct 2018 | 440 | - | Fibroscan <8 (-F2 and below) | Steatosis on imaging; ALT >1.5xULN 3 months apart | Improvement in liver stiffness by Fibroscan at 2 years |
| MGL-3196 | Selective THR-β agonist | (NCT02912260; Madrigal Pharmaceuticals, West Conshohocken, PA, USA) | Sep 2017 | 117 | <45 | F1–3 | Biopsy | Imaging - Change in hepatic fat fraction on MRI-PDFF at 12 weeks |
| Volixibat (SHP626) | ASBT inhibitor | (NCT02787304; Shire Pharmaceuticals, Dublin, Ireland) | Jul 2020 | 266 | - | F0–3 | Biopsy and MRI for steatosis | Histologic improvement - ≥2 point improvement in NAS without worsening of fibrosis at 48 weeks |
| GS-9674 | FXR agonist | (NCT02854605; Gilead Sciences, Foster City, CA, USA) | Jan 2018 | 125 | ≥18 | F1–3 | Biopsy or MRE | Safety - emergent adverse events and laboratory abnormalities at “up to 24 weeks plus 30 days” |
| Semaglutide | GLP-1 analogue | (NCT02970942; Novo Nordisk, Bagsvaerd, Denmark) | Jul 2019 | 372 | 25–45 | F2–3 | Biopsy | Histologic improvement - NAS resolution without worsening of fibrosis at 48 weeks |
| Saroglitazar | PPAR-α/γ agonist | EVIDENCES II (NCT03061721; Zydus Discovery, Ahmedabad, India) | Jun 2018 | 104 | 25–40 | F0–3 | Biopsy, ultrasound, CT, or MRI | Change in aminotransferases at 16 weeks |

(continued)
| Drug (Alias) | Mechanism | Study Name (ClinicalTrials.gov ID; Sponsor) | Target Completion Date | Target Enrollment | BMI as kg/m^2 | Fibrosis Stage | Diagnosis | Inclusion/Exclusion Criteria | Primary Outcome Measures |
|-------------|------------|---------------------------------------------|-----------------------|------------------|--------------|---------------|-----------|---------------------------|--------------------------|
| AZ compound | Not specified | (NCT02605616; Mayo Clinic, Rochester, MN, USA) | Dec 2017 | 100 | 19–40 | F2 or greater fibrosis | Biopsy/MRE proven | | Imaging - change in liver fat fraction at 12 weeks |
| LMB763 | FXR agonist | (NCT02913105; Novartis, Geneva, Switzerland) | Oct 2018 | 100 | – | – | Biopsy + ALT elevation, or elevated ALT + BMI + DM2 | Adverse event profile and safety endpoints at 12 weeks |
| IVA337 | Pan-PPAR agonist | NATIVE (NCT03008070; Inventiva, Daix, France) | Jun 2018 | 225 | <45 | <F4 | Biopsy | Histologic improvement - >2 point improvement in SAF score without worsening of fibrosis |
| LJN452 | FXR agonist | FLIGHT-FXR (NCT02855164; Novartis, Geneva, Switzerland) | Nov 2017 | 250 | – | – | Biopsy + ALT elevation, or elevated ALT + BMI + DM2 | Adverse event profile at 12 weeks |
| CF102 | A3AR agonist | (NCT02927314; Can-Fite BioPharma, Petah-Tikva, Israel) | Feb 2018 | 60 | ≤40 | Absence of cirrhosis (Fibroscan score ≤F4 + LSM of 7.13 kPa) | NMRS | Percent change in the liver triglyceride concentration on NMRS at 12 weeks |
| MT-3995 | Mineralocorticoid receptor antagonist | (NCT02923154; Mitsubishi Tanabe Pharma, Osaka, Japan) | Oct 2017 | 40 | – | – | – | Percent change in ALT at 24 weeks |
| Pioglitazone | PPAR-γ agonist | (NCT01068444; Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan) | Mar 2018 | 90 | – | Up to (compensated) cirrhosis | Biopsy | Steatosis and liver function tests at 9 months |
| MN-001 (tipelukast) | Small molecule | (NCT02681055; MediciNova, La Jolla, CA, USA) | Jun 2017 | 40 | ≤45 | Excludes cirrhosis | Biopsy-proven NASH or ultrasound confirmed NAFLD | Cholesterol efflux capacity and triglyceride levels at 12 weeks |
| MSDC-0602K | PPAR-γ sparing mTOT modulator | EMMINENCE (NCT02784444; Cirius Therapeutics, Kalamazoo, MI, USA) | Oct 2018 | 200 | – | F1–3 | Biopsy | Histological improvement - decrease in NAS without worsening of fibrosis at 12 months |

(continued)
Table 2. (continued)

| Drug (Alias) | Mechanism                                      | Study Name (ClinicalTrials.gov ID; Sponsor)                                      | Target Completion Date | Target Enrollment | Inclusion/Exclusion Criteria                                                                 | BMI as kg/m² | Fibrosis Stage | Diagnosis               | Primary Outcome Measures                          |
|-------------|-------------------------------------------------|----------------------------------------------------------------------------------|------------------------|------------------|-----------------------------------------------------------------------------------------------|--------------|-----------------|--------------------------|--------------------------------------------------|
| JKB-121     | TLR-4 antagonist/non-selective opioid antagonist | (NCT02442687; Manal Abdelmalek, Duke University Medical Center, Durham, NC, USA) | Jul 2017              | 66               | • Adverse events at 24 weeks <br> • Percent change in fat content on MRI/NMRS at 24 weeks <br> • Change in ALT at 24 weeks <br> • Time to remission (two consecutive ALT within normal limits) at 24 weeks | ≥25          | F0–3           | Biopsy                  |                                                                                       |
| IMM-124E    | Gut microbiome modulator                        | (NCT02316717; Immuron, Armadale, Australia)                                      | Oct 2017              | 130              | • Percent change in fat content on MRI at 24 weeks <br> • ALT, other laboratory measures, and vitals at 24 weeks | ≥25          | F0–3           | Biopsy                  |                                                                                       |
| ARI-3037MO  | Synthetic analog of nicotinic acid              | (NCT02574325; Arisaph, Boston, MA, USA)                                          | Oct 2016              | 11               | • Percent change in fat content on MRI at 24 weeks <br> • ALT and triglycerides at 24 weeks                                                                 | 28–45        | MRI and lab elevation |                                                                                       |
| Drug (Alias) | Mechanism | Study Name | Study Design | Population | Results |
|-------------|-----------|------------|--------------|------------|---------|
| Obeticholic acid (OCA) | FXR ligand | FLINT | Phase 2b U.S. multicenter, double-blind, RCT comparing obeticholic acid 25 mg daily to placebo for 72 weeks (n = 283) | Adults with biopsy-proven, non-cirrhotic NASH with NAS ≥4, with ≥1 of each component of the score* | • Primary endpoint (improvement in NAS ≥2 points without worsening of fibrosis) met in 50/110 (45%) patients in the intervention arm vs. 23/109 (23%) patients in the placebo arm (p < 0.001)  
• Fibrosis improved in 36/102 (35%) patients in the intervention arm vs. 19/98 (19%) patients in the placebo arm (p = 0.004) |
| Elafibranor (GFT505) | PPAR-α/δ agonist | GOLDEN-505 | Phase 2b USA and Europe multicenter, double-blind, RCT comparing elafibranor 80 mg and 120 mg daily to placebo for 52 weeks (n = 276) | Adults with biopsy-proven, non-cirrhotic NASH with NAS ≥3, with ≥1 of each component of the score* | • Protocol-defined primary outcome (reversal of NASH defined by the absence of at least 1 of steatosis, ballooning, and inflammation without progression to bridging fibrosis or cirrhosis) not significantly different between arms  
• Modified definition of response (resolution of NASH as defined by disappearance of ballooning with disappearance or mild persistence of lobular inflammation and a pathologic diagnosis of steatosis ± mild inflammation and no worsening of fibrosis) met in 17/89 (19%) patients in the 120 mg arm vs. 11/92 (12%) in the placebo arm (p = 0.045)  
• Fibrosis stage was significantly reduced in responders based on the modified definition (to 120 mg vs. non-responders)  
• Fibrosis improved in 13/30 (43%) patients in the 18 mg ± simtuzumab arm vs. 8/27 (30%) patients in the 6 mg ± simtuzumab arm vs. 2/10 (20%) patients receiving simtuzumab monotherapy  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition) |
| Selonsertib (GS-4997) | ASK-1 inhibitor |  | Phase 2 U.S. and Canada multicenter, open-label, RCT comparing selonsertib 6 mg and 18 mg daily ± simtuzumab to simtuzumab monotherapy for 24 weeks (n = 72) | Adults with biopsy-proven F2–3 NASH with NAS ≥5 | • Fibrosis improved (without worsening of steatohepatitis) in 13/30 (43%) patients in the 18 mg ± simtuzumab arm vs. 8/27 (30%) patients in the 6 mg ± simtuzumab arm vs. 2/10 (20%) patients receiving simtuzumab monotherapy  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition)  
• Mostly dose-dependent trends observed in responders (based on the modified definition) |
| Cenicriviroc (CVC) | Dual CCR2/CCR5 antagonist | CENTAUR | Phase 2b multinational multicenter, double-blind, RCT comparing cenicriviroc 150 mg daily to placebo for 2 years (n = 289) | Adults with biopsy-proven F1–3 NASH with NAS ≥4 and diabetes or metabolic syndrome | • Pre-specified primary endpoint (≥2-point improvement in NAS [with ≥1-point reduction in lobular inflammation or ballooning] and no worsening of fibrosis) met at 1 year interim analysis  
• Fibrosis improved (without worsening of steatohepatitis) in 29/145 (20%) patients in the intervention arm vs. 15/144 (10%) patients in the placebo arm (p = 0.023), most pronounced in subjects with higher disease activity and stage, at 1 year interim analysis |

*NAS (NAFLD activity score) scored as steatosis 0–3, ballooning 0–2, and lobular inflammation 0–3.

Abbreviations: ASK, apoptosis signal-regulating kinase; CCR, C-C motif chemokine receptor; FXR, farnesoid X nuclear receptor; MRE, magnetic resonance elastography; MRI-PDFF, magnetic resonance imaging-estimated proton density fat fraction; NAS, NAFLD activity score; NASH, non-alcoholic steatohepatitis; PPAR, peroxisome proliferator-activated receptor; RCT, randomized controlled trial.
Selonsertib was well-tolerated overall, although key adverse effects included fatigue, headache and nausea. STELLAR-3 is a multinational phase 3 randomized, placebo-controlled, double-blind clinical trial designed to assess the safety and efficacy of selonsertib 6 mg and 18 mg in patients with stage F3 fibrosis. STELLAR-4 is a phase 3 randomized, placebo-controlled, double-blind clinical trial which evaluates the safety and efficacy of selonsertib in patients with compensated cirrhosis. The primary outcomes for both protocols are liver fibrosis regression ≥1 stage at 48 weeks, and event-free survival at 240 weeks. They are currently recruiting with a target enrollment of 800 participants, each with an estimated completion date of January 2020.

**CVC:** CVC is an oral, dual CCR2/CCR5 inhibitor owned by Tobira Therapeutics (San Francisco, CA, USA). In animal fibrosis models it is demonstrated to have anti-inflammatory and antifibrotic properties.56-57 CVC is being evaluated in phase 2 and phase 3 trials.

CENTAUR (NCT02217475), a phase 2b study of CVC in 289 patients with F1-F3 fibrosis and one or more of diabetes, body mass index above 25 kg/m² with features of metabolic syndrome, and bridging fibrosis (or definite NASH), is fully enrolled and ongoing (Table 3). The 1 year primary analysis showed that in the intent-to-treat population, the primary endpoint, a ≥2-point improvement in NAS (with ≥1-point reduction in lobular inflammation or hepatocyte ballooning) and no worsening of fibrosis, was not met.58 However, twice as many CVC-treated subjects (29/145 [20%]) compared to placebo (15/144 [10%]) attained ≥1 stage improvement in fibrosis without worsening of steatohepatitis (p = 0.023). A subgroup analysis of this secondary endpoint identified predictors of response, including NAS ≥5, hepatocellular ballooning grade ≥2, and fibrosis stages F2-F3 (p = 0.049).

AURORA (NCT03028740) is a phase 3 trial of CVC, targeting patients with F2-F3 fibrosis and having an anticipated enrollment of 2000. Primary outcome measures include: 1) histologic improvement of histologic progression to cirrhosis, liver-related clinical outcomes, and all-cause mortality. The estimated primary completion date is January 2020.

**Liraglutide:** Liraglutide is a glucagon-like peptide (GLP)-1 analogue approved by the FDA for the treatment of type II diabetes and is marketed under the brand name Victoza. Liraglutide recently demonstrated encouraging results for patients with NASH in several small, randomized trials,59,60 including the phase 2 LEAN study sponsored by its manufacturer, Novo Nordisk ( Bagsvaerd, Denmark). In this double-blind, multicenter trial, 52 participants with biopsy-proven NASH (stage F0-F4 fibrosis) were randomized to receive liraglutide or placebo for 48 weeks. The primary outcome was resolution of definitive NASH without worsening of fibrosis from baseline to end of treatment. In the modified intention-to-treat analysis, nine of 23 (39%) patients treated with liraglutide with pre- and posttreatment biopsies had resolution of NASH versus two of 22 (9%) such patients in the placebo group. Patients receiving liraglutide experienced an improvement in weight and hemoglobin A1c, although no significant change in total NAS or fibrosis stage was observed. Although liraglutide will not be further evaluated in phase 3 development, Novo Nordisk has initiated a phase 2b trial (NCT02970942) evaluating another GLP-1 analogue, semaglutide (Table 2) versus placebo in 372 participants with stage F2-F3 fibrosis and NAS ≤4 with a score of at least 1 for each of the components (steatosis, ballooning, and lobular inflammation). The primary outcome is NASH resolution without worsening of fibrosis, and the estimated primary completion date for this protocol is 2019.

**Metadoxine:** Metadoxine (pyridoxine-L-2-pyrrolidone-5-carboxylate) is an antioxidant that is proposed to be a source of glutathione, capable of inhibiting adipocyte differentiation, limiting hepatic lipid accumulation, and exerting antifibrotic properties.61-63 It has largely been studied in patients with alcoholic steatosis64 and alcoholic hepatitis,65,66 and may have a role in managing acute alcohol intoxication,67 alcohol dependence,68 and attention-deficit/hyperactivity disorder.69

In the only significant randomized controlled trial in patients with NASH, metadoxine was compared to placebo for 16 weeks in 134 participants with stage F0-F3 fibrosis.70 Although it did not improve liver histology or serum aminotransferases compared to placebo, it did improve steatosis assessed by ultrasound. This improvement in steatosis is consistent with prior results in patients with alcoholic liver disease.64 A proposed phase 3 trial in Mexico (NCT02541045) of metadoxine in overweight and obese patients with stage F0-F2 fibrosis is currently seeking to enroll 108 patients. The primary outcome is improvement in NAS score at six months and the trial has an estimated completion date of August 2018.

**Drugs in phase 2 trials**

Approximately two-dozen phase 2 clinical trials are currently actively looking at novel pharmacotherapies for adults with NASH (Table 2). Of these, only the following three have publicly published results: CVC, as mentioned above in the CENTAUR trial; NGM282 (NGM Biopharmaceuticals, Inc, South San Francisco, CA, USA); and BMS-986036 (Bristol-Myers Squibb, Princeton, NJ, USA).

**NGM282:** NGM282 (formerly known as M70) is a non-tumorigenic, engineered variant of fibroblast growth factor (FGF)-19 that acts through FGF receptors 1c and 4 to reduce steatosis and lipotoxicity. It was studied in a randomized, double-blind, placebo controlled phase 2 trial (NCT02443116) in 82 patients with biopsy-proven non-cirrhotic NASH with ≥8% absolute liver fat content by MRI proton density fat fraction (MRI-PDFF). The primary outcome was a ≥5% reduction in absolute liver fat content as measured by MRI-PDFF after 12 weeks of treatment. The results were presented at The International Liver Congress 2017 and demonstrated that 79% of NGM282-treated subjects met the primary outcome compared with 7% in the placebo group.71 Other findings included lower alanine aminotransferase values and lower enhanced liver fibrosis scores72 for the treatment groups, but higher LDL levels were also observed.73 Similar results were seen in a phase 2 trial in patients with PBC.74 No information is available regarding design of potential phase 2b or 3 trials.

**BMS-986036:** BMS-986036 is a pegylated analogue of FGF-21 that has been shown to decrease hepatic steatosis, NAS and fibrosis in a mouse model of NASH, and to have beneficial effects on insulin sensitivity, lipids and fibrotic markers in obese diabetic patients with a high prevalence of NAFLD.76,77 The results of a phase 2 randomized, double-blind, placebo controlled trial (NCT02413372) involving 74 participants with a body mass index ≥25 kg/m², biopsy-proven non-cirrhotic NASH, and ≥10% absolute liver fat content by MRI-PDFF were presented at The International Liver Congress 2017.78 The primary outcome, a change in percent hepatic fat fraction by MRI-PDFF after 16 weeks of
Looking ahead

With the recent advent of highly effective oral direct-acting antiviral agents for the treatment of hepatitis C virus, the prevalence of hepatitis C and its associated burden of liver cirrhosis and its complications is expected to decline. Concurrently, NASH is rapidly emerging as the most common cause of liver cirrhosis and liver failure requiring liver transplantation. In context of a limited treatment paradigm focused on medical weight loss without a single FDA-approved pharmacotherapy for NASH, there exists significant interest in novel agents that may meaningfully alter the natural history of the disease. Several agents are currently in phase 3 clinical trials, and are expected to reach completion within the next 2–4 years. The regulatory framework for drug development remains focused on two pathways to approval, including: 1) NASH resolution without worsening of liver fibrosis; and 2) histologic regression of liver fibrosis of at least one stage without worsening NASH.

Although key clinical development programs have largely evaluated single agents for NASH therapy, future treatment paradigms may involve combination regimens which incorporate two or more complementary mechanisms of action that target metabolic, inflammation, and/or fibrosis factors and/or pathways to optimize efficacy in NASH resolution and liver fibrosis regression. Due to the established association between NASH and both cardiovascular disease and malignancy, careful attention to off-target adverse effects will be essential. Ongoing scientific advances in the pathogenesis of NASH and identification of novel agents addressing key targets of disease activity will be necessary to further expand our capacity to both treat NASH and reduce long-term clinical outcomes, including cirrhosis, liver failure and liver cancer.

Conflict of interest

JKL reports research contracts from Allergan, Conatus, Genfit, Gilead, Intercept, and Prometheus. The others have no conflict of interests related to this publication.

Author contributions

Drafting of the manuscript (JJC, KO, JKL), contributing to the conception and design of the study (JJC, KO, JKL), contributing to critical revisions of the manuscript (JKL).

References

[1] Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005–2023. doi: 10.1002/hep.25762.
[2] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Weym Y. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73–84. doi: 10.1002/hep.28431.
[3] Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States. Hepatology 2016;64:1577–1586. doi: 10.1002/hep.26785.
[4] Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547–555. doi: 10.1053/j.gastro.2014.11.039.
[5] Goldberg D, Ditah IC, Saenai K, Lalehzari M, Aronsohn A, Gorospe EC, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 2017;152:1090–1099.e1. doi: 10.1053/j.gastro.2017.01.003.
[6] Said A, Akhter A. Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis. Ann Hepatol 2017;16:538–547. doi: 10.1016/j.ajh.2016.01.0284.
[7] Lombardi R, Onali S, Thorburn D, Davidson BR, Gurumary KS, Tsoshatze A. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011640. doi: 10.1002/14651858.CD011640.pub2.
[8] Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology 2015;62:1417–1432. doi: 10.1002/hep.27999.
[9] Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliwer SA, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1360–1368.
[10] Cariou B, van Harmelen K, Durr-Sandoval D, van Dijk TH, Grefforst A, Abdelkarim M, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem 2006;281:11039–11049. doi: 10.1074/jbc.M510256200.
[11] Watanabe M, Houten SM, Wang L, Moschetta A, Mangelis DJ, Heyman RA, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004;113:1408–1418. doi: 10.1172/JCI21025.
[12] Gimeno RE, Moller DE. FGF21-based pharmacotherapy—potential utility for metabolic disorders. Trends Endocrinol Metab 2014;25:303–311. doi: 10.1016/j.tem.2014.03.001.
[13] Cicione C, Degirolamo C, Moschetta A. Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. Hepatology 2012;56:2404–2411. doi: 10.1002/hep.25299.
[14] Krhantonenkov A, Wroblewski VJ, Koester A, Chen YP, Clutingter CK, Tigno XT, et al. The metabolic state of non-human primates is regulated by fibroblast growth factor-21. Endocrinology 2007;148:774–781. doi: 10.1210/en.2006-1168.
[15] Bhatnagar S, Damron HA, Hillgartner FB. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 2009;284:10023–10033. doi: 10.1074/jbc.M808812200.
[16] Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient-deficiency. Endocrinology 2004;145:2594–2603. doi: 10.1210/en.2003-1671.
[17] Alvarez-Sola G, Uriarte I, Lataza MU, Fernandez-Barrena MG, Urtasun R, Elizalde M, et al. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatoasis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration. Gut 2017;66:1818–1828. doi: 10.1136/gutjnl-2016-312975.
[18] Gaich G, Chien YJ, Fu H, Glass LC, Deeg MA, Holland WL, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013;18:333–340. doi: 10.1016/j.cmet.2013.08.005.
[19] Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, et al. A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab 2016;23:427–440. doi: 10.1016/j.cmet.2016.02.001.
[20] Ferni N, Corsini A, Sirtori C, Russcia M. PPARa agonists are still on the rise: an update on clinical and experimental findings. Expert Opin Investig Drugs 2017;26:593–602. doi: 10.1080/13543784.2017.1312339.
[21] Staels B, Dalongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088–2093. doi: 10.1161/01.cir.98.19.2088.
[22] Luquet S, Gaudel C, Holst D, Lopez-Soriano J, Jeh-Petri C, Frederich A, et al. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim Biophys Acta 2005;1750:313–317. doi: 10.1016/j.bbadis.2004.11.011.
[23] Gilby VG, Alith TA. Role of adipokines and pexoxisomal proliferator-activated receptors in nonalcoholic fatty liver disease. World J Hepatol 2014;6:570–579. doi: 10.4245/wjh.v6.i8.570.
[24] Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Intermediate results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatology 2003;38:434–440. doi: 10.1016/S0168-8278(03)00027-8.
dependence and alcoholic liver disease. Hum Psychopharmacol 2011;26:554–559. doi: 10.1002/hup.1244.

[69] Manor I, Ben-Hayun R, Aharon-Peretz J, Salomy D, Weizman A, Daniely Y, et al. A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2012;73:1517–1523. doi: 10.4088/JCP.12m07767.

[70] Shenoy KT, Balakumaran LK, Mathew P, Prasad M, Prabhakar B, Sood A, et al. Metadoxine Versus Placebo for the Treatment of Non-alcoholic Steatohepatitis: A Randomized Controlled Trial. J Clin Exp Hepatol 2014;4:94-100. doi: 10.1016/j.jceh.2014.03.041.

[71] Harrison SA, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, et al. NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients. J Hepatol 2017;66:S92–S93. doi: 10.1016/S0168-8278(17)30448-8.

[72] Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol 2013;59:236–242. doi: 10.1016/j.jhep.2013.03.016.

[73] Luo J, Ko B, Ding X, Rossi S, DePaoli A, Tian H. Serum cholesterol changes associated with NGM282 treatment in obese insulin resistant cynomolgus monkeys are reversed with either a statin or a PCSK9 inhibitor. J Hepatol 2017;66:S430. doi: 10.1016/S0168-8278(17)31227-8.

[74] Mayo MJ, Wigg AJ, Roberts SK, Arnold H, Hassanein TI, Leggett BA, et al. NGM282, a novel variant of FGF-19, demonstrates biologic activity in primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid: results of a phase 2 multicenter, randomized, double blinded, placebo controlled trial. Hepatology 2015;62:263A–264A.

[75] Krupinski J, Morgan N, Kozich A, Chiney M, Morin R, Christian R. Effects of BMS-986036 (pegylated fibroblast growth factor 21) on hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology 2016;64:749A.

[76] Charles ED, Morrow L, Honpesch M, Luo Y, Wu CK, Christian R. A phase 1 study of BMS-986036 (pegylated FGF21) in healthy obese subjects. Hepatology 2016;64:S546A.

[77] Charles ED, Tetri BA, Luo Y, Wu CK, Christian R. A phase 2 study of BMS-986036 (pegylated FGF21) in obese adults with type 2 diabetes and a high prevalence of fatty liver. Hepatology 2016:64:17A.

[78] Sanyal A, Charles ED, Neuschwander-Tetri B, Loomba R, Harrison S, Abdelmalek M, et al. BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study. J Hepatol 2017;66:S89–S90. doi: 10.1016/S0168-8278(17)30443-9.

[79] Bristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) shows consistent improvement in liver fat, liver injury and fibrosis in patients with nonalcoholic steatohepatitis (NASH) in phase 2 trial. Princeton 2017. Available from: https://news.bms.com/press-release/bmy/bristol-myers-squibbs-bms-986036-pegylated-fgf21-shows-consistent-improvement-live.